Weight-Loss Drugs' Gains Lift Pharma R&D Returns, but 'Bubble' Risk Grows

Deloitte UK and Deloitte US analysis finds projected R&D returns rose for the third straight year — driven largely by GLP‑1 assets, as obesity overtakes oncology as the largest contributor to late-stage pipeline value for the first time in 16 years. NEW YORK, May 4, 2026 /PRNewswire/ --...